Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral monepantel dose-escalation study in treatment-refractory advanced solid tumors
ACTRN12614000612617Phase 2Terminated
- Sponsor
- Neurizon Therapeutics
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of monepantel in Nonhematologic neoplasms (4 arms), sponsored by Neurizon Therapeutics. Primary endpoints: Safety, tolerability, dose-limiting toxicities, and maximum tolerated dose of monepantel and Multiple-dose pharmacokinetics of monepantel. Started Jun 2014; status: terminated.
02
Drugs
monepantel
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ACTRN12614000612617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000612617.